Inhibition of the release of soluble tumor necrosis factor receptors in experimental endotoxemia by an anti-tumor necrosis factor-α antibody

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Clinical Immunology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/BF01489489PMID 7759600
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense?

  1995cited by this paper
• Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees.

  1994cited by this paper
• Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees.

  1993cited by this paper
• Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists.

  1993cited by this paper
• Detection of tumor necrosis factor soluble receptor p55 in blood samples from healthy and endotoxemic humans.

  1993cited by this paper
• Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia.

  1993cited by this paper
• Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. The J5 Study Group.

  1992cited by this paper
• Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia.

  1992cited by this paper
• Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo.

  1992influential reference
• Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors

  1992cited by this paper
• Administration of tumor necrosis factor α(TNFα) inhibitors after exposure to TNFα prevents development of the maximal biological effect : an argument for clinical treatment with TNFα inhibitors

  1992cited by this paper
• High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia.

  1992cited by this paper
• Administration of tumor necrosis factor alpha (TNF alpha) inhibitors after exposure to TNF alpha prevents development of the maximal biological effect: an argument for clinical treatment with TNF alpha inhibitors.

  1992cited by this paper
• Mobilizable intracellular pool of p55 (type I) tumor necrosis factor receptors in human neutrophils

  1992cited by this paper
• Efficacy of monoclonal antibody against human recombinant tumor necrosis factor in E. coli-challenged swine.

  1992cited by this paper
• Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific.

  1991cited by this paper
• Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor. Comparison with the proteolytic activity responsible for shedding of TNF receptors from stimulated neutrophils.

  1991cited by this paper
• On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin.

  1991cited by this paper
• The pathogenesis of sepsis.

  1991cited by this paper
• Molecular cloning and expression of a receptor for human tumor necrosis factor.

  1990cited by this paper
• Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans.

  1990cited by this paper
• Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences.

  1990cited by this paper
• Shedding of tumor necrosis factor receptors by activated human neutrophils

  1990cited by this paper
• A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor.

  1990cited by this paper
• Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients.

  1990cited by this paper
• A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins.

  1990cited by this paper
• Characterization in vitro of a human tumor necrosis factor-binding protein. A soluble form of a tumor necrosis factor receptor.

  1990cited by this paper
• Complementary DNA cloning of a receptor for tumor necrosis factor and demonstration of a shed form of the receptor.

  1990cited by this paper
• Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies.

  1990cited by this paper
• Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors.

  1990cited by this paper
• Activation of coagulation after administration of tumor necrosis factor to normal subjects.

  1990cited by this paper
• Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein.

  1990cited by this paper
• Soluble forms of tumor necrosis factor receptors (TNF‐Rs). The cDNA for the type I TNF‐R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor.

  1990cited by this paper
• Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor.

  1990cited by this paper
• Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor.

  1990cited by this paper
• Isolation and characterization of a tumor necrosis factor binding protein from urine

  1989cited by this paper
• Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor.

  1989cited by this paper
• A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity.

  1989cited by this paper
• A human inhibitor of tumor necrosis factor alpha

  1988cited by this paper
• A tumor necrosis factor binding protein is present in human biological fluids

  1988cited by this paper
• A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes.

  1986cited by this paper
• Quantification and characterization of high‐affinity membrane receptors for tumor necrosis factor on human leukemic cell lines

  1986cited by this paper
• Cellular receptor for 125I-labeled tumor necrosis factor: specific binding, affinity labeling, and relationship to sensitivity.

  1985cited by this paper
• Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor a in vitro and in vivo

  year unknowncited by this paper

• 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future

  2021cites this paper
• Tumor Necrosis Factor Alpha: Role in the Development of Obesity and Diabetes Mellitus

  2020cites this paper
• Upregulation of cytokine mRNA in circulating leukocytes during human endotoxemia

  2017cites this paper
• IMMUNITY ACTIVATION IN HIV INFECTION

  2017cites this paper
• Serum concentrations and renal expressions of IL-1 and TNF-a early after hemorrhage in rats under the effect of glibenclamide.

  2016cites this paper
• Soluble Fn14 Is Detected and Elevated in Mouse and Human Kidney Disease

  2016cites this paper
• NGAL and other markers of inflammation as competitive or complementary markers for depressive symptom dimensions in heart failure

  2015cites this paper
• Targeting of Tumor Necrosis Factor Alpha Receptors as a Therapeutic Strategy for Neurodegenerative Disorders

  2015cites this paper
• Characterization of Soluble Biomarkers and Regulatory B Cell Subset Useful to Improve Systemic Scleroderma Clinical Diagnosis and Management

  2015cites this paper
• A Soluble TNF Receptor 2 Agonist as a New Therapeutic Approach to Treat Autoimmune and Demyelinating Diseases

  2011cites this paper
• Systematic review of chimpanzee use in monoclonal antibody research and drug development: 1981-2010.

  2011cites this paper
• Tumor Necrosis Factor and Anti-Tumor Necrosis Factor Therapies

  2010cites this paper
• TNF receptor 2 pathway: drug target for autoimmune diseases

  2010cites this paper
• Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists.

  2010cites this paper
• The −383A>C TNFRI polymorphism is associated with soluble levels and clinical activity in rheumatoid arthritis

  2010cites this paper
• Endothelin-A Receptor Inhibition Following Cardiopulmonary Bypass: Cytokines and Receptor Activation

  2009cites this paper
• Cytokines and matrix metalloproteinases as potential biomarkers in chronic heart failure.

  2009cites this paper
• Endothelin-A receptor inhibition after cardiopulmonary bypass: cytokines and receptor activation.

  2008cites this paper
• Review: From therapy to experimental model: a hundred years of endotoxin administration to human subjects

  2007cites this paper
• Modulation of the systemic inflammatory response by recombinant human interleukin-11: a prospective randomized placebo controlled clinical study in patients with hematological malignancy.

  2006cites this paper
• the tumour necrosis factor receptor-associated periodic syndrome: current concepts

  2005cites this paper
• A novel adenovirus mediated gene therapy approach improves survival in a murine model of endotoxic shock

  2005cites this paper
• Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use.

  2005cites this paper
• Tumor Necrosis Factor (TNF) Receptor Shedding Controls Thresholds of Innate Immune Activation That Balance Opposing TNF Functions in Infectious and Inflammatory Diseases

  2004cites this paper
• Anti-inflammatory response after infusion of p55 soluble tumor necrosis factor receptor fusion protein for severe sepsis.

  2003cites this paper
• Regulatory role of cytokines in disseminated intravascular coagulation.

  2001cites this paper
• The effect of a metalloproteinase inhibitor (GI5402) on tumor necrosis factor-alpha (TNF-alpha) and TNF-alpha receptors during human endotoxemia.

  1999cites this paper
• Roles of IL-1 and TNF in the decreased ileal muscle contractility induced by lipopolysaccharide.

  1999cites this paper
• Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia.

  1997cites this paper
• Down-regulation of surface receptors for TNF and IL-1 on circulating monocytes and granulocytes during human endotoxemia: effect of neutralization of endotoxin-induced TNF activity by infusion of a recombinant dimeric TNF receptor.

  1997cites this paper
• Relationship of plasma HIV-RNA levels and levels of TNF-alpha and immune activation products in HIV infection.

  1997cites this paper
• Tumor necrosis factor-alpha enhances antitumor effects of radiation against glioma xenografts.

  1997cites this paper
• Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock.

  1997cites this paper
• Epinephrine attenuates down‐regulation of monocyte tumor necrosis factor receptors during human endotoxemia

  1997cites this paper
• Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion.

  1997cites this paper
• Cytokines as mediators in the pathogenesis of septic shock.

  1996cites this paper
• Endogenous IL-10 protects mice from death during septic peritonitis.

  1995cites this paper
• Tumor necrosis factor alpha and interleukin-1 alpha stimulate late shedding of p75 TNF receptors but not p55 TNF receptors from human monocytes.

  1995cites this paper
• Recombinant endotoxin-binding protein (rBPI23) attenuates endotoxin-induced circulatory changes in humans.

  1995cites this paper